Skip to content

MAZE MAZE Preferred Stock

Preferred Stock at other companies

Zymeworks logo
ZymeworksZYME
$0
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$0
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$0
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$0
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$0

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B+201%
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's preferred stock?
MAZE (MAZE) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.